; and (2) the term opioid-sparing means reducing, replacing, or avoiding the use of opioids or other controlled substances intended to treat acute or chronic pain. 3002. Evidence-based opioid analgesic prescribing guidelines and report (a) Guidelines The Commissioner of Food and Drugs shall develop evidence-based opioid analgesic prescribing guidelines for the indication-specific treatment of acute pain only for the relevant therapeutic areas where such guidelines do not exist. (b) Public input In developing the guidelines under subsection (a), the Commissioner of Food and Drugs shall— (1) consult with stakeholders, which may include conducting a public meeting of medical professional societies (including any State-based societies), health care providers, State medical boards, medical specialties including pain medicine specialty societies, patient groups, pharmacists, academic or medical research entities, and other entities with experience in health care, as appropriate; (2) collaborate with the Director of the Centers for Disease Control and Prevention, as applicable and appropriate, and other Federal agencies with relevant expertise as appropriate